These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 18816890)

  • 1. [Ezetimibe=cost effectiveness. Science or a debate contribution from MSD?].
    Lindberg M
    Ugeskr Laeger; 2008 Sep; 170(38):2987; author reply 2988. PubMed ID: 18816890
    [No Abstract]   [Full Text] [Related]  

  • 2. Ezetimibe--an update.
    Drug Ther Bull; 2009 Aug; 47(8):91-5. PubMed ID: 19654419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The evidence of clinical effects of ezetimibe is not sufficient].
    Heebøll-Nielsen NC; Holme P
    Ugeskr Laeger; 2008 Sep; 170(38):2987; author reply 2988. PubMed ID: 18819180
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pfizer: TLV decision about antilipemic agents is founded on wrong basis].
    Brun J; Ohlsson-Onerud A; Sörensen N
    Lakartidningen; 2009 Apr 22-28; 106(17):1193-4; discussion 1194. PubMed ID: 19530431
    [No Abstract]   [Full Text] [Related]  

  • 5. [Lean years for patients].
    Klose G; Anlauf M
    MMW Fortschr Med; 2004 Dec; 146(51-52):16. PubMed ID: 15675237
    [No Abstract]   [Full Text] [Related]  

  • 6. Money, money, money.
    Drug Ther Bull; 2010 Jul; 48(7):73. PubMed ID: 20631194
    [No Abstract]   [Full Text] [Related]  

  • 7. Alirocumab's Price Reduction.
    Dhruva SS; Ross JS; Desai NR
    Circulation; 2018 Oct; 138(15):1502-1504. PubMed ID: 30354510
    [No Abstract]   [Full Text] [Related]  

  • 8. Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia: NICE technology appraisal guidance.
    Charles Z; Pugh E; Barnett D
    Heart; 2008 May; 94(5):642-3. PubMed ID: 18411354
    [No Abstract]   [Full Text] [Related]  

  • 9. Ezetimibe 5 and 10 mg for lowering LDL-C: potential billion-dollar savings with improved tolerability.
    Baruch L; Gupta B; Lieberman-Blum SS; Agarwal S; Eng C
    Am J Manag Care; 2008 Oct; 14(10):637-41. PubMed ID: 18837641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The right pill for growth. The high cost of developing blockbuster drugs forces big makers into bigger mergers.
    Fischer JS
    US News World Rep; 1999 Nov; 127(19):56. PubMed ID: 10623304
    [No Abstract]   [Full Text] [Related]  

  • 11. [New lower cholesterol levels: How much does it cost? Who is to pay?].
    Lindberg M
    Ugeskr Laeger; 2004 Nov; 166(49):4493-4; author reply 4494. PubMed ID: 15626108
    [No Abstract]   [Full Text] [Related]  

  • 12. [Research and marketing].
    Meland E; Hernborg A
    Tidsskr Nor Laegeforen; 2004 Jul; 124(13-14):1820. PubMed ID: 15229677
    [No Abstract]   [Full Text] [Related]  

  • 13. Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment.
    Lane JD; Friedberg MW; Bennett CL
    JAMA Oncol; 2016 Feb; 2(2):274-6. PubMed ID: 26658959
    [No Abstract]   [Full Text] [Related]  

  • 14. [Isn't it good if one person out of 600 treated with statins will get better?].
    Molander N
    Lakartidningen; 2004 Jul; 101(28-29):2365. PubMed ID: 15291322
    [No Abstract]   [Full Text] [Related]  

  • 15. Pill profits.
    Barnett M
    US News World Rep; 2003 Dec; 135(22):40-1. PubMed ID: 14712783
    [No Abstract]   [Full Text] [Related]  

  • 16. PHARMAC at what cost?
    Moodie P; McNee W
    N Z Med J; 2000 Feb; 113(1104):64. PubMed ID: 10777230
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia.
    Almutairi F; Peterson TC; Molinari M; Walsh MJ; Alwayn I; Peltekian KM
    Liver Transpl; 2009 May; 15(5):504-8. PubMed ID: 19399742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Contribution to anticholesteremic agents?].
    Astrup P; Gyntelberg F
    Ugeskr Laeger; 1998 Jun; 160(24):3574-6. PubMed ID: 9641049
    [No Abstract]   [Full Text] [Related]  

  • 19. An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach.
    Halleck M; Davis HR; Kirschmeier P; Levitan D; Snyder RD; Treinen K; Macdonald JS
    Toxicology; 2009 Apr; 258(2-3):116-30. PubMed ID: 19428931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MSD "regrets" tactics used to silence doctor over prescription advice.
    Turone F
    BMJ; 2014 Jul; 349():g4599. PubMed ID: 25022568
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.